Drug Profile
LY 3541105
Alternative Names: DACRA QW II; Dacra-QW-II - Eli Lilly and Company; LY-3541105Latest Information Update: 01 Jun 2022
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Obesity therapies
- Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 10 May 2022 Phase-I clinical trials in Obesity in USA (SC) (NCT05380323)